Long-Acting Cabotegravir Well Tolerated in Pregnant Women
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 8, 2024 -- Long-acting injectable cabotegravir (CAB-LA) appears to be well tolerated in pregnant women, according to a study presented at AIDS 2024, the 25th International AIDS Conference, held from July 22 to 26 in Munich.
Sinead Delany-Moretlwe, M.B.B.Ch., Ph.D., from the University of the Witwatersrand in South Africa, and colleagues reported on maternal safety and pregnancy outcomes among 2,472 participants in the HPTN 084 open-label extension. Pregnancies were categorized by exposure to CAB-LA injections during pregnancy, CAB-LA injections before pregnancy only, and no CAB-LA exposure (tenofovir disoproxil fumarate/emtricitabine [TDF/FTC] group).
The researchers identified 351 confirmed incident pregnancies in 334 participants during 3,118 person-years (incidence, 11.3/100 person-years). The median time from last injection to pregnancy detection was eight and 13 weeks among participants with CAB-LA use during or prior to pregnancy, respectively. Participants with CAB-LA use during pregnancy received a median of four injections. No maternal deaths were reported. The incidence of pregnancy-related maternal adverse events was 43.7, 52.9, and 40.0 per 100 person-years among those using CAB-LA during pregnancy, those using prior to pregnancy, or those without CAB-LA exposure, respectively. Across groups, poor pregnancy outcome rates were similar, with negative outcomes reported in 28, 35, and 26 percent of pregnancies with CAB-LA use during pregnancy, prior to pregnancy, or without CAB-LA exposure, respectively. There was one major congenital anomaly (in the group receiving CAB-LA during pregnancy).
"We hope that these findings can fill an important knowledge gap that can help increase access to this highly effective HIV preexposure prophylaxis option among cisgender women before, during, and after pregnancy," Delany-Moretlwe said in statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2024
Read this next
Pesticide Exposure Tied to Increased Risk for Stillbirth
TUESDAY, Aug. 13, 2024 -- Pesticide exposures during preconception and the first trimester may be associated with stillbirth, according to a study published online July 16 in...
Hep C Reinfection Observed in HIV-Positive Men Who Have Sex With Men
THURSDAY, Aug. 8, 2024 -- The incidence rate of hepatitis C virus (HCV) reinfection was 4.7 per 100 person-years among men who have sex with men (MSM) with HIV who cleared HCV...
Risk for Sudden Unexpected Infant Death Increased With Maternal Obesity
WEDNESDAY, July 31, 2024 -- Infants born to mothers with obesity have an increased risk for sudden unexpected infant death (SUID), according to a study published online July 29 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.